{"id":501186,"date":"2020-08-07T21:46:02","date_gmt":"2020-08-07T21:46:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=501186"},"modified":"2020-08-07T21:46:02","modified_gmt":"2020-08-07T21:46:02","slug":"iga-nephropathy-igan-pipeline-assessment-key-companies-and-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/iga-nephropathy-igan-pipeline-assessment-key-companies-and-emerging-drugs_501186.html","title":{"rendered":"IgA Nephropathy (IgAN) Pipeline Assessment, Key Companies And Emerging Drugs"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"IgA Nephropathy (IgAN) Pipeline Assessment, Key Companies And Emerging Drugs\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"IgA Nephropathy (IgAN) Pipeline Assessment, Key Companies And Emerging Drugs\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;IgA Nephropathy (IgAN) Pipeline Insight, 2020&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the IgA Nephropathy (IgAN) market. <\/p>\n<\/div>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">The&nbsp;<strong>IgA Nephropathy (IgAN) Pipeline<\/strong> report provides in-depth <\/span><span data-mce-mark=\"1\">commercial assessment and clinical assessment<\/span><span data-mce-mark=\"1\"> of the IgA Nephropathy (IgAN) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IgA Nephropathy (IgAN) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Get FREE sample copy at:&nbsp;<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/iga-nephropathy-igan-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/iga-nephropathy-igan-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"iga-nephropathy-igan-pipeline-insight\" src=\"https:\/\/www.abnewswire.com\/uploads\/812d88ba1a7bbca57fde11fe357fdca7.jpg\" alt=\"iga-nephropathy-igan-pipeline-insight\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>The current pipeline for IgA Nephropathy has many significant products. The dynamics of IgA Nephropathy market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also due to the expected launch of many therapies during the forecast period.<\/strong><br \/><strong>Some of the Key players involved in the development of therapies for the treatment of IgA Nephropathy includes:<\/strong><br \/>Novartis<br \/>Omeros Corporation<br \/>Calliditas Therapeutics<br \/>Apellis Pharmaceuticals<br \/>Aravive<br \/>Ionis<br \/>Aduro Biotech<br \/>and many others<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs Covered <\/strong><br \/>OMS721 <br \/>Nefecon<br \/>APL-2<br \/>LNP023<br \/>AVB-500 <br \/>BION-1301 <br \/>And many others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-pipeline-insight\" target=\"_blank\"><strong><span data-mce-mark=\"1\">IgA Nephropathy (IgAN) Pipeline Analysis<\/span><\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The report provides insights into:&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The report provides detailed insights about companies that are developing therapies for the <\/span><span data-mce-mark=\"1\">treatment of IgA Nephropathy (IgAN)<\/span><span data-mce-mark=\"1\"> with aggregate therapies developed by each company for the same.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the <strong>IgA Nephropathy (IgAN) treatment<\/strong>.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">IgA Nephropathy (IgAN) key players<\/span><\/strong><span data-mce-mark=\"1\"> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of <\/span><strong><span data-mce-mark=\"1\">IgA Nephropathy (IgAN) market<\/span><\/strong><span data-mce-mark=\"1\">.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Scope of the report<\/span><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The IgA Nephropathy (IgAN) Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and<\/span><span data-mce-mark=\"1\"> MOA type for IgA Nephropathy (IgAN)<\/span><span data-mce-mark=\"1\"> across the complete product development cycle, including all clinical and nonclinical stages.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">It comprises of detailed profiles of <\/span><strong><span data-mce-mark=\"1\">IgA Nephropathy (IgAN) therapeutic products<\/span><\/strong><span data-mce-mark=\"1\"> with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Detailed <\/span><span data-mce-mark=\"1\"><strong>IgA Nephropathy (IgAN) research and development<\/strong> progress and trial details<\/span><span data-mce-mark=\"1\">, results wherever available, are also included in the pipeline study.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Coverage of dormant and discontinued pipeline projects along with the reasons if available across IgA Nephropathy (IgAN).<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Report Highlights<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">A better understanding of disease pathogenesis contributing to the development of <\/span><span data-mce-mark=\"1\">novel therapeutics for IgA Nephropathy (IgAN)<\/span><span data-mce-mark=\"1\">.&nbsp;&nbsp;&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">In the coming years, the <strong>IgA Nephropathy (IgAN) market<\/strong> is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The companies and academics that are working to assess challenges and seek opportunities that could influence <strong>IgA Nephropathy (IgAN) R&amp;D<\/strong>. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">A detailed portfolio of major pharma players who are involved in fueling the <\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-pipeline-insight\" target=\"_blank\"><strong><span data-mce-mark=\"1\">IgA Nephropathy (IgAN) treatment market<\/span><\/strong><\/a><span data-mce-mark=\"1\">. Several potential therapies for IgA Nephropathy (IgAN) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the IgA Nephropathy (IgAN) market size in the coming years.&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">Our in-depth analysis of the pipeline assets (in <\/span><strong><span data-mce-mark=\"1\">early-stage, mid-stage and late stage of development for the treatment of IgA Nephropathy (IgAN)<\/span><\/strong><span data-mce-mark=\"1\"><strong>)<\/strong> includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">2. IgA Nephropathy (IgAN)&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">3. IgA Nephropathy (IgAN) Current Treatment Patterns<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">4. IgA Nephropathy (IgAN) &#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">5. Therapeutic Assessment<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">6. IgA Nephropathy (IgAN) Late Stage Products (Phase-III)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">7. IgA Nephropathy (IgAN) Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">12. IgA Nephropathy (IgAN) Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">13. IgA Nephropathy (IgAN) Product Profiles<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">14. IgA Nephropathy (IgAN) Key Companies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">15. IgA Nephropathy (IgAN) Key Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">16. Dormant and Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">17. IgA Nephropathy (IgAN) Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">18. IgA Nephropathy (IgAN) Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">19. IgA Nephropathy (IgAN) Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">21. Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Related Reports<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-market\"><span data-mce-mark=\"1\">IgA Nephropathy (IgAN) Market Insight, Epidemiology and Market Forecast -2030<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s &#8220;IgA Nephropathy (IgAN) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the IgA Nephropathy (IgAN) , historical and forecasted epidemiology as well as the IgA Nephropathy (IgAN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/span><\/span><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-epidemiology-forecast\"><span data-mce-mark=\"1\">IgA Nephropathy (IgAN) Epidemiology Forecast to 2030<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s IgA Nephropathy (IgAN) &#8211; Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of IgA Nephropathy (IgAN) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Anuj Rawat<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=iga-nephropathy-igan-pipeline-assessment-key-companies-and-emerging-drugs\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=iga-nephropathy-igan-pipeline-assessment-key-companies-and-emerging-drugs\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research &#8220;IgA Nephropathy (IgAN) Pipeline Insight, 2020&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the IgA Nephropathy (IgAN) market. The&nbsp;IgA Nephropathy (IgAN) Pipeline report provides in-depth commercial assessment and clinical &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/iga-nephropathy-igan-pipeline-assessment-key-companies-and-emerging-drugs_501186.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-501186","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=501186"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501186\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=501186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=501186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=501186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}